TRT Monitoring & Management Clinic in Kent

There is a conversation I have regularly at Juvenology that has nothing to do with aesthetics. A man in his 40s or 50s sits down and tells me he has been on testosterone replacement therapy for a year, sometimes two or three years. He feels better than he did before. His energy has improved, his mood has lifted, his gym performance has come back.

Then I ask when he last had a blood panel.

The answer is almost always the same. The initial test that got him prescribed. Maybe one follow-up. Nothing since.

That gap is not just an administrative problem. In my cardiac nursing years, I spent a long time watching what happens when physiological changes go untracked. Elevated viscosity that nobody noticed for months. Haematocrit climbing incrementally while the patient felt fine and the prescription renewed. The consequences do not arrive with a warning. They accumulate quietly until they are not quiet anymore.

TRT is not a supplement. It is a medical intervention that creates real, measurable physiological changes throughout the body: in your red blood cell count, your cardiovascular markers, your liver function, your prostate, your bone density, and your skin. Every one of those systems needs looking at regularly. Not once at the start and then forgotten as the repeat prescription ticks along.

This article is for men who are on TRT, men who are considering it, and men who want to understand what responsible long-term management of this therapy actually looks like. At Juvenology we run a comprehensive blood panel service specifically designed to give men on TRT the full clinical picture their prescribers should be tracking. Here is what that means and why it matters.

What TRT is doing to your body

Testosterone does not work in isolation. Once you introduce exogenous testosterone, your body responds across multiple systems simultaneously, and not all of those responses are immediately obvious.

Your red blood cell production increases. Testosterone stimulates the kidneys to produce erythropoietin, which signals the bone marrow to make more red blood cells. Your oestradiol levels may rise as the aromatase enzyme, concentrated in fat tissue, converts testosterone to oestrogen. Your natural testosterone production is suppressed, because the hypothalamus detects sufficient circulating testosterone and stops signalling the testes. Your PSA may shift modestly. Your lipid profile may change. Your haematocrit, the proportion of your blood occupied by red blood cells, climbs.

None of this is a reason to avoid TRT if you are genuinely deficient and symptomatic. All of it is manageable. But all of it needs watching. The difference between TRT that works safely over many years and TRT that creates problems is almost entirely a question of how well the monitoring is done and how consistently it is maintained.

What UK guidelines say

The British Society for Sexual Medicine is the leading UK authority on testosterone deficiency and treatment. Its guidelines are unambiguous: blood tests before starting TRT, then at 3, 6, and 12 months, and annually thereafter once levels are stable. The European Expert Panel on Testosterone Research reviewed the landmark TRAVERSE trial data in 2025 and aligned with this schedule, adding specific timing guidance for gels, injectables, and long-acting depot formulations.

Here is what many men do not realise. Checking whether your testosterone level is within range is actually the smallest part of what monitoring is for. The markers that carry the most significant safety implications are haematocrit, PSA, and oestradiol. These are also the ones most likely to fall through the gaps in online and GP-led TRT care. Let me go through each of them properly.

The markers that actually matter

Total and free testosterone

The starting point, but not the whole picture. Total testosterone measures the gross level in your blood, but a significant portion is bound to a protein called sex hormone-binding globulin, SHBG, which renders it biologically inactive. The fraction that is not bound to SHBG is free testosterone, and that is what your tissues actually use.

The typical target range on TRT is 15 to 30 nmol/L for total testosterone, with free testosterone in the upper part of the reference range. Consistently below 15 suggests underdosing. Consistently above 30 raises the side-effect risk profile. The timing of your test relative to your last dose matters as much as the result itself. For injectables like Sustanon or Nebido, test at trough, just before your next injection, to capture the lowest point in your cycle. For gels, test 2 to 4 hours after application.

SHBG

SHBG determines how much of your total testosterone is actually available to your tissues. High SHBG means less free testosterone reaching cells, which explains why some men remain symptomatic with a total testosterone reading that looks perfectly adequate on paper. Low SHBG, more common in men with obesity, insulin resistance, or high-dose TRT, means more free testosterone available but also faster metabolism and greater conversion to oestradiol. You cannot make clinical sense of your testosterone results without knowing your SHBG.

Haematocrit and full blood count

This is the marker I most want men to understand, because it carries the most immediate safety implications and is the most consistently under-monitored in TRT care.

Testosterone stimulates erythropoietin production in the kidneys, which drives the bone marrow to produce more red blood cells. This effect is dose and concentration dependent. It is more pronounced with short-acting injectable testosterone, particularly Sustanon, which produces high peak concentrations after each injection, than with gels, which provide more stable day-to-day levels.

As haematocrit rises, blood becomes more viscous. Flow slows. A haematocrit above 54% is the threshold at which the BSSM, the Endocrine Society, and the European Association of Urology all recommend intervention: dose reduction, formulation change, or therapeutic phlebotomy, the medically supervised removal of blood to reduce red cell concentration. Research published in the Journal of Urology found that polycythaemia developing on TRT independently increases the risk of venous thromboembolism and major cardiovascular events, particularly in the first year of therapy.

The risk factors that accelerate haematocrit rise on TRT include injectable testosterone, older age, smoking, untreated sleep apnoea, obesity, and high altitude. Men with any of these factors need haematocrit checked every three months in the first year, not every six.

The TRAVERSE trial, the largest randomised controlled trial of testosterone therapy ever conducted, with 5,246 participants, confirmed that TRT does not increase overall risk of major adverse cardiac events. It did identify higher rates of atrial fibrillation and pulmonary embolism in the testosterone group. Haematocrit monitoring is how those risks are managed. It is not optional scaffolding around the therapy. It is part of the therapy itself.

I watched elevated viscosity go undetected in cardiac patients for months at a time. The clinical picture that followed was rarely subtle. A haematocrit that nobody caught is one of the most preventable risks in TRT management and one of the most commonly missed.

PSA

PSA monitoring on TRT is essential and often misunderstood. Current evidence, including the TRAVERSE trial and the 2023 BSSM guidelines, does not support the historical concern that TRT causes prostate cancer. Prostate cancer rates in the TRAVERSE trial were essentially identical between the testosterone and placebo groups.

What TRT does do is stimulate existing prostate tissue, producing a modest, predictable PSA rise of roughly 0.3 to 0.5 ng/mL in the first year, which then plateaus. That is expected and not itself concerning. What requires investigation is a rise of more than 1.4 ng/mL within 12 months of starting, or an absolute PSA above 4.0 ng/mL in men over 50. Both thresholds should prompt urology referral.

The practical point is simple. Without a baseline PSA before starting TRT, any subsequent reading has no context. You cannot interpret a number you have nothing to compare it against.

Oestradiol

Testosterone is converted to oestradiol through aromatisation, primarily in fat tissue. This is normal male physiology. Men need oestrogen for bone density, cardiovascular health, and sexual function. The clinical problem arises when oestradiol rises disproportionately, which is more likely in men with higher body fat, on higher TRT doses, or using injectable testosterone with pronounced peaks.

Elevated oestradiol in men on TRT produces a recognisable symptom picture: gynaecomastia, water retention, emotional lability, reduced libido despite adequate testosterone, fatigue, skin oiliness, and acne. The target range is broadly 80 to 150 pmol/L. Levels consistently above 200 pmol/L warrant a conversation about dose or formulation adjustment.

Aromatase inhibitors are sometimes prescribed to manage high oestradiol on TRT. Their use is increasingly contested. Research referenced in an FDA submission in 2025 noted that aromatase inhibitors in men worsen lipid profiles, increase cardiovascular risk, and accelerate bone loss. I would want any man considering them to understand that evidence clearly before agreeing to a protocol that routinely includes them.

Lipid profile

TRT tends to reduce HDL cholesterol, the protective fraction, and in some studies modestly increases LDL. How clinically significant those changes are depends on your baseline cardiovascular risk, your diet, your exercise habits, and your metabolic health. Monitoring lipids at 3 and 6 months after starting TRT, and annually thereafter, gives you early sight of any adverse trend before it becomes a problem.

Liver function

Modern injectable and gel testosterone formulations carry far less hepatotoxicity risk than the oral preparations used historically. Periodic liver function testing remains standard protocol regardless, both as a safety check and because liver function directly influences SHBG production and therefore your free testosterone picture.

HbA1c and fasting glucose

Men with low testosterone are at meaningfully higher risk of insulin resistance and type 2 diabetes. The BSSM notes that TRT in men with pre-diabetes and testosterone below 14 nmol/L has been shown to reduce progression to type 2 diabetes by 40% over two years. That is a striking metabolic benefit that goes well beyond libido and gym performance. Including HbA1c and fasting glucose in a comprehensive TRT panel allows early intervention if insulin sensitivity is deteriorating despite treatment.

Bone density

Low testosterone is strongly associated with reduced bone mineral density and increased fracture risk. TRT improves bone density in hypogonadal men, and the TRAVERSE trial confirmed meaningful fracture reduction. For men starting TRT with established bone density concerns, or those who have been on therapy for several years without a DEXA scan, baseline and follow-up bone density assessment gives important long-term context.

Hair density

Hair is more complicated. Testosterone does not cause male pattern baldness directly. Its conversion to DHT via 5-alpha reductase accelerates follicular miniaturisation in men who are genetically susceptible. That said, testosterone replacement in genuinely deficient men has in some studies supported hair recovery in areas affected by telogen effluvium linked to the deficiency itself. If hair thinning is a concern on TRT, DHT level and genetic susceptibility are the relevant variables. Our PRP scalp treatment supports follicular health in men experiencing TRT-related thinning, particularly where DHT sensitivity is the driver.

Why so many men on TRT in the UK are under-monitored

NHS TRT access is limited by strict diagnostic thresholds. Total testosterone below 8.6 nmol/L combined with clear symptoms is typically required for treatment, and ongoing monitoring, while adequate by minimum standards, is usually annual at best, covering testosterone level, full blood count, liver function, and PSA. Free testosterone, SHBG, oestradiol, lipids, and HbA1c rarely feature. Private TRT clinics vary considerably. Some run rigorous comprehensive panels and thorough follow-up. Others prescribe testosterone with minimal oversight, guided more by commercial pressure than clinical responsibility. Online services are particularly inconsistent.

The result is a large group of men on TRT who feel better than they did before treatment but who are not being monitored closely enough to catch the markers that cause problems over time. A haematocrit climbing quietly for six months. A PSA that has risen 1.8 ng/mL from baseline with no urology referral triggered. An oestradiol level that perfectly explains why libido has dropped despite apparently adequate testosterone. These are not unusual clinical scenarios. They are what happens when monitoring is inadequate.

What the Juvenology TRT blood panel includes

Our Advanced Blood Panel is built to provide the complete monitoring picture that TRT requires, interpreted in the context of how you feel and how you are responding to treatment, not just a set of numbers measured against a reference range.

For men on TRT, we include total testosterone and free testosterone, SHBG, oestradiol, LH and FSH, haematocrit and full blood count, PSA, lipid profile, liver function, kidney function, HbA1c and fasting glucose, and thyroid function.

We time the blood draw to your formulation. Trough for injectables. Mid-cycle for gels. Because the timing of the test is as clinically important as the test itself, and most services do not communicate this clearly or apply it consistently.

For men experiencing skin changes alongside hormonal changes, oiliness, acne, laxity, hair thinning, the panel provides the hormonal context that allows us to address those concerns properly. Where regenerative skin treatments are appropriate, we can integrate them with your TRT monitoring in the same appointment.

A note on fertility

TRT suppresses the hypothalamic-pituitary-gonadal axis, which reduces or eliminates sperm production. Men who want to preserve future fertility should discuss this with their prescriber before starting TRT, not after. LH and FSH monitoring gives some indication of whether endogenous production is being suppressed, but it is not a reliable contraceptive measure and should not be treated as one.

Book your TRT blood panel at Juvenology

If you are on TRT in Kent and your monitoring has been incomplete, inconsistent, or simply too infrequent, or if you want a thorough clinical review of where your biology currently stands, that is exactly what the Juvenology blood panel service is for.

Book your comprehensive blood panel at Juvenology

In twenty-five years of nursing, first in cardiology and then in longevity medicine, the cases that have stayed with me are not the ones where something went dramatically wrong. They are the ones where it went quietly wrong, incrementally, over months, while the patient felt broadly fine and the prescription renewed. The haematocrit that crept above 54% with nobody checking. The PSA rise that crossed the referral threshold and nobody acted on it. These are preventable. Comprehensive, timely blood monitoring is not the administrative surround to TRT. It is the clinical foundation on which safe, effective long-term therapy depends.

We see patients from across Kent including Maidstone, Tonbridge, Sevenoaks, Kings Hill, West Malling, Medway, and Chatham.

Clinical references

1. BSSM Guidelines on Male Adult Testosterone Deficiency, 2023: pmc.ncbi.nlm.nih.gov/articles/PMC10307648

2. BSSM Practical Guide on Testosterone Assessment and Management, 2023: bssm.org.uk

3. Cardiovascular Safety of Testosterone Replacement Therapy, TRAVERSE Trial, NEJM: nejm.org

4. Cardiovascular Safety of Testosterone Therapy, European Expert Panel Position Statement, 2025: pmc.ncbi.nlm.nih.gov/articles/PMC12670475

5. Testosterone Therapy in Men with Hypogonadism, Endocrine Society Clinical Practice Guideline: academic.oup.com

6. TRT Blood Tests UK, Monitoring Guide, Lola Health: lolahealth.com